Title:
EGFR-BINDING PEPTIDE
Document Type and Number:
WIPO Patent Application WO/2014/002836
Kind Code:
A1
Abstract:
Provided are: a substance capable of binding to an EGFR specifically with a high affinity; and a medicinal agent comprising the substance.
A peptide which comprises at least the amino acid sequence represented by formula (1), (2) or (3) and is composed of 12 to 50 amino acid residues.
X1-His-X2-X3-Asp-X4-X5-X6-X7-X8-Trp-His (1)
(In formula (1), X1 represents Trp or Phe; X2 represents Leu, Met, Ile or Val; X3 represents Ser, Ala, Thr, Gly, Asn, Asp, Glu, Arg or Lys; X4 represents Leu, Met, Ile, Val, Ala, Phe, Tyr, Trp, His or Cys; X5 represents Trp, Phe or Tyr; X6 represents Gln, Asn, Asp, Glu, Ala, Ser, Thr, Leu, Met, Lys or Arg; X7 represents Asn, Gln, Asp, Glu, Ser, Thr, Ala, Gly, Lys or Arg; and X8 represents Ala, Gly, Ser, Thr, Asn, Val or Cys.)
Phe-His-Asp-Trp-X11-Pro-X12-X13-X14-X15-X16-X17 (2)
(In formula (2), X11 represents Leu, Met, Ile, Val, Ala, Phe, Tyr, Trp, His or Cys; X12 represents Glu, Asp, Gln, Asn, Ala, Ser, Thr, Lys, Arg or His; X3 represents Val, Ala, Leu, Ile, Met, Thr, Cys or Asn; X14 represents Ser, Ala, Thr, Gly, Asn, Asp, Glu, Arg or Lys; X5 represents Pro, Val, Ile, Lys, Ala, Met, Trp, Tyr, Ser, Thr, Cys or Phe; X16 represents Pro, Val, Ile, Lys, Ala, Met, Trp, Tyr, Ser, Thr, Cys or Phe; and X17 represents Asp, Glu, Asn, Gln, Ala, Ser, Thr, Lys, Arg or His.)
Leu-His-X21-Ser-X22-Trp-Met-X23-X24-X25-X26-X27 (3)
(In formula (3), X21 represents Gln, Asn, Asp, Glu, Ala, Ser, Thr, Leu, Met, Lys or Arg; X22 represents Glu, Asp, Gln, Asn, Ala, Ser, Thr, Lys, Arg or His; X23 represents Tyr, Phe, Trp, His, Leu, Met, Ile, Val, Cys or Ala; X24 represents Val, Ala, Leu, Ile, Met, Thr, Cys or Asn; X25 represents Asp, Glu, Asn, Gln, Ala, Ser, Thr, Lys, Arg or His; X26 represents Ile, Val, Leu, Met, Ala, Phe, Tyr, Trp or Gly; and X27 represents His, Tyr, Phe, Lys, Arg, Leu, Met or Ala.)
Inventors:
IIMORI YUSUKE (JP)
YAMAGATA MIZUE (JP)
SHIONO TOSHITAKA (JP)
YAMAGATA MIZUE (JP)
SHIONO TOSHITAKA (JP)
Application Number:
PCT/JP2013/066762
Publication Date:
January 03, 2014
Filing Date:
June 18, 2013
Export Citation:
Assignee:
HOYA CORP (JP)
International Classes:
C07K7/08; A61K38/00; A61P35/00; C07K14/00; G01N33/574; C12N15/09
Domestic Patent References:
| WO1996040210A1 | 1996-12-19 |
Foreign References:
| JP4808412B2 | 2011-11-02 |
Other References:
LI Z. ET AL.: "Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics", FASEB J., vol. 19, no. 14, December 2005 (2005-12-01), pages 1978 - 1985, XP002394913
ABOURBEH G. ET AL.: "PolyIC GE11 Polyplex Inhibits EGFR-Overexpressing Tumors", IUBMB LIFE, vol. 64, no. 4, April 2012 (2012-04-01), pages 324 - 330, XP055183776
JEONG M.H. ET AL.: "In vivo and in vitro evaluation of Cy5.5 conjugated epidermal growth factor receptor binding peptide", NUCL. MED. BIOL., vol. 39, no. 6, 14 March 2012 (2012-03-14), pages 805 - 812, XP028431839
HAMZEH-MIVEHROUD M. ET AL.: "Identification of new peptide ligands for epidermal growth factor receptor using phage display and computationally modeling their mode of binding", CHEM. BIOL. DRUG DES., vol. 79, no. 3, March 2012 (2012-03-01), pages 246 - 259, XP055183893
THE FASEB JOURNAL, vol. 19, 2005, pages 1978 - 1985
JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 97, no. 22, 2005, pages 1663 - 1670
ABOURBEH G. ET AL.: "PolyIC GE11 Polyplex Inhibits EGFR-Overexpressing Tumors", IUBMB LIFE, vol. 64, no. 4, April 2012 (2012-04-01), pages 324 - 330, XP055183776
JEONG M.H. ET AL.: "In vivo and in vitro evaluation of Cy5.5 conjugated epidermal growth factor receptor binding peptide", NUCL. MED. BIOL., vol. 39, no. 6, 14 March 2012 (2012-03-14), pages 805 - 812, XP028431839
HAMZEH-MIVEHROUD M. ET AL.: "Identification of new peptide ligands for epidermal growth factor receptor using phage display and computationally modeling their mode of binding", CHEM. BIOL. DRUG DES., vol. 79, no. 3, March 2012 (2012-03-01), pages 246 - 259, XP055183893
THE FASEB JOURNAL, vol. 19, 2005, pages 1978 - 1985
JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 97, no. 22, 2005, pages 1663 - 1670
Attorney, Agent or Firm:
THE PATENT CORPORATE BODY ARUGA PATENT OFFICE (JP)
Patent business corporation Alga patent firm (JP)
Patent business corporation Alga patent firm (JP)
Download PDF: